DOCSLIB.ORG

Fenofibrate Ezetimibe Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fenofibrate Ezetimibe Studies FenofibrateFenofibrate EzetimibeEzetimibe SurrogateSurrogate TrialsTrials ThomasThomas Dayspring,Dayspring, MD,MD, FACPFACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph’s Hospital, Paterson, NJ Certified Menopause Practitioner: North American Menopause Society North Jersey Institute of Menopausal Lipidology PharmacokineticPharmacokinetic DataData FenofibrateFenofibrate –– EzetimibeEzetimibe PharmacodynamicPharmacodynamic andand PharmacokineticPharmacokinetic InteractionInteraction StudyStudy Placebo (n = 8) Ezetimibe 10 mg (n = 8) Patients have no physical 30 activity and are on a high Fenofibrate 200 mg (n = 8) carbohydrate low fat diet which lowers HDL-C 20 Fenofibrate 200mg + 10 Ezetimibe 10 mg (n = 8) 0 -10 -20 -30 Change from Baseline (%) -40 -50 TC LDL-C HDL-C TG Mean (SE) percentage change from baseline in serum lipids on day 14 following oral administration of fenofibrate monotherapy, ezetimibe monotherapy, fenofibrate-ezetimibe co- administration therapy or placebo once daily to 14 healthy subjects with hypercholesterolemia Kosoglou T et al. Curr Med Res & Opin 2004;20:1185-1195 FenofibrateFenofibrate –– EzetimibeEzetimibe PharmacodynamicPharmacodynamic andand PharmacokineticPharmacokinetic InteractionInteraction StudyStudy Placebo (n = 8) 30 Ezetimibe 10 mg (n = 8) Fenofibrate 200 mg (n = 8) Combination therapy 20 produced significantly Fenofibrate 200mg + 10 Ezetimibe 10 mg (n = 8) greater reductions in 0 LDL-C and in small LDL-III -10 Levels of apoCIII were -20 also reduced greater -30 than monotherapy with Change from Baseline (%) either drug -40 -50 LDL-C LDL-1 LDL-II LDL-III Large Intermed Small Kosoglou T et al. Curr Med Res & Opin 2004;20:1185-1195 FenofibrateFenofibrate –– EzetimibeEzetimibe PharmacodynamicPharmacodynamic andand PharmacokineticPharmacokinetic InteractionInteraction StudyStudy 8.0 180 Ezetimibe 10 mg (n = 8) 7.0 160 Fenofibrate 200mg + Ezetimibe 10 mg (n = 8) Ezetimibe 10 mg (n = 8) 6.0 140 Fenofibrate 200mg + 120 5.0 Ezetimibe 10 mg (n = 8) 100 4.0 80 3.0 60 1.0 40 Ezetimibe Conc (ng/ml) 20 1.0 Total Ezetimibe Conc (ng/ml) 0 0 0 4812 16 20 24 0 4 81216 20 24 Time (hr) Time (hr) Mean (+SD) plasma concentration-time profiles of total ezetimibe (ezetimibe + ezetimibe glucuronide) and ezetimibe on day 14 following multiple dose, once-daily oral administration of either ezetimibe alone or co-administered with fenofibrate Concomitant fenofibrate administered as a 200 mg micronized capsule formulation resulted in a significant (~50%) increase in the steady state total ezetimibe exposure. However, this exposure is probably not clinically important. The increased plasma total ezetimibe appear to be due to an increase in ezetimibe bioavailability rather than inhibition of clearance Kosoglou T et al. Curr Med Res & Opin 2004;20:1185-1195 EzetimibeEzetimibe -- FenofibrateFenofibrate PharmacokineticPharmacokinetic StudyStudy ) EzetimibeEzetimibe hadhad nono clinicallyclinically significantsignificant effecteffect onon thethe pharmacokineticspharmacokinetics (e.g.(e.g. absorbtionabsorbtion,, metabolismmetabolism andand excretion)excretion) oror pharmacodynamicspharmacodynamics (e.g.(e.g. bindingbinding actionaction ofof thethe drugdrug toto certaincertain receptorsreceptors andand consequentconsequent effectseffects onon CNS,CNS, GIGI tracttract andand otherother CVCV parameters)parameters) ofof fenofibratefenofibrate oror vicevice versaversa.. www.sch-plough.com/news/2001/research/20010521.html EzetimibeEzetimibe -- FenofibrateFenofibrate PharmacokineticPharmacokinetic StudyStudy 32 patients with hypercholesterolemia for 14 days: on strict diet LDL-C TG (median) HDL-C 0% Mean % Change From Baseline -20% -30% -32% Placebo Zetia -36%* TriCor *P≤0.03 vs placebo or either drug. Combo ZaijkaZaijka StudyStudy FenofibrateFenofibrate –– EzetimibeEzetimibe CombinationCombination TherapyTherapy 50 Mixed dyslipidemia patients who cannot tolerate a statin Baseline Fenofibrate 160 mg Fenofibrate + Ezetimibe 10 mg 280 500 46 12.5%* * 45 437 44 200 31%* 43 * 375 42 * 41 312 32%* 40 39 250 100 187 * Concentration in mg/dL Concentration in mg/dL 69%* 125 20 TC LDL-C HDL-C TG * p<0.01 compared to baseline Zaijka, P. Poster Presentation NLA Annual Meeting Orlando, Fl Aug 2004 FarnierFarnier StudyStudy (Abstract(Abstract && Publication)Publication) EzetimibeEzetimibe –– FenofibrateFenofibrate StudyStudy After a six- to eight-week washout period, patients with mixed hyperlipidemia LDL cholesterol between 130 and 220 mg/dL (between 100 and 180 mg/dL for type 2 diabetics) and triglycerides between 200 and 500 mg/dL were randomized in a 1:3:3:3 ratio to one of four daily treatments: Placebo (n=64). After the completion of Ezetimibe 10 mg (n=187). this double-blind, placebo-controlled Fenofibrate 160 mg (n=189). study, the trial is to be Ezetimibe 10 mg and fenofibrate 160 mg (n=185). extended for an additional 48 weeks The primary end point of the study compared the LDL-cholesterol reduction efficacy of fenofibrate plus ezetimibe vs fenofibrate alone at 12 weeks. Farnier M et al. Drugs Affecting Lipid Metabolism 2004 meeting, October 24-27, 2004; Venice, Italy. EzetimibeEzetimibe –– FenofibrateFenofibrate StudyStudy End point Placebo Ezetimibe Fenofibrate Ezetimibe 10 mg + (n=64) 10 mg 160 mg fenofibrate 160 (n=187) (n=189) mg (n=185) LDL cholesterol 0.2 -13.4 -5.5 -20.4 (% change)* HDL cholesterol 3.2 3.9 18.8 19.0 (% change) Triglycerides -9.2 -11.1 -43.2 -44.0 (% change) Non-HDL -0.2 -14.7 -16.2 -30.4 cholesterol (% change) ApoB (% change) -1.2 -11.3 -15.2 -26.1 High-sensitivity 9.1 -6.1 -28.0 -27.3 CRP (% change) Fibrinogen -0.3 -0.3 -10.1 -11.5 (% change) Percent change in study end points *Indicates primary end point Farnier M et al. Drugs Affecting Lipid Metabolism 2004 meeting, October 24-27, 2004; Venice, Italy. EzetimibeEzetimibe –– FenofibrateFenofibrate StudyStudy Placebo Ezetimibe Fenofibrate Combination 20 18.8 19.0 10 9.1 3.2 3.9 0.2 0 0.2 1.2 .3 .3 5.5 6.1 9.2 -10 11.3 10.1 11.1 11.5 13 14.7 15.2 16.2 -20 20 26.1 -30 28 27.3 30.4 -40 43.2 42 -50 LDL-C HDL-C TG Non HDL-C ApoB hs-CRP Fibrinogen Farnier M et al. Drugs Affecting Lipid Metabolism 2004 meeting, October 24-27, 2004; Venice, Italy. EzetimibeEzetimibe –– FenofibrateFenofibrate StudyStudy ) Fenofibrate and Ezetimibe administered together produced significant, positive benefits on the atherogenic lipid profiles and the inflammation biomarker, hs-CRP, in patients with mixed hyperlipidemia. ) Depending on the study variable, the effects of coadministration of Fenofibrate and Ezetimibe were either additive (LDL-C, TC, non-HDL-C, and apo B) or Fenofibrate-dependent (TG, HDL-C, apo A-I, hs-CRP, fibrinogen, and LDL size pattern shift). ) Moreover, co-administered Fenofibrate and Ezetimibe demonstrated a good safety profile that was comparable to Fenofibrate alone. Farnier M, et al. Eur Heart J. 2005;26:897-905. EzetimibeEzetimibe –– FenofibrateFenofibrate StudyStudy ) Per cent reduction in LDL-C was greater with EZE treatment compared with FENO alone, but LDL-C reduction was additive when both FENO and EZE were used together. ) However, the change in LDL-C was influenced by baseline TG levels in patients with mixed hyperlipidemia in the present study. ) Greater LDL-C lowering was noted with all active treatments in patients with baseline < TG 250 mg/dL. • In contrast, in the high TG subgroup, FENO treatment produced virtually no change in LDL-C, whereas the effect of EZE was maintained. Farnier M, et al. Eur Heart J. 2005;26:897-905. EzetimibeEzetimibe –– FenofibrateFenofibrate StudyStudy % Achieving NCEP ATP III Goals 70 Placebo Ezetimibe Fenofibrate Combination 60 More than 62% of patients shifted to 50 the larger, more buoyant LDL 40 pattern from the smaller, more 30 dense pattern with 20 coadministration, and FENO alone 10 treatments. Proportion attaining target (%) Proportion attaining target (%) 0 LDL-C Non HDL-C Baseline: LDL-C ~ 140 HDL-C ~ 40 TG ~ 240240 The Non HDL-C goal attainment was comparable across baseline TG values Farnier M, et al. Eur Heart J. 2005;26:897-905. FenofibrateFenofibrate andand EzetimibeEzetimibe CombinationCombination EffectsEffects Ezetimibe Fenofibrate Combination 20 10 0 -<1 -10 -6 -10 -11 -20 † † -30 -28 -27 † † Change From Baseline, % -40 -50 hsCRP Fibrinogen †P<.05 versus ezetimibe Farnier M, et al. Eur Heart J. 2005;26:897-905 EzetimibeEzetimibe –– FenofibrateFenofibrate StudyStudy TheThe coadministrationcoadministration ofof EzetimibeEzetimibe withwith FenofibrateFenofibrate offersoffers aa wellwell--toleratedtolerated newnew lipidlipid managementmanagement strategystrategy forfor patientspatients withwith mixedmixed hyperlipidemiahyperlipidemia inin thisthis study.study. TheThe combinedcombined useuse ofof thesethese agentsagents providesprovides aa therapytherapy withwith complementarycomplementary effectseffects toto improveimprove thethe atherogenicatherogenic lipidlipid profileprofile observedobserved forfor thesethese patients.patients. Farnier M, et al. Eur Heart J. 2005;26:897-905. DIACORDIACOR TheThe DIACORDIACOR StudyStudy TripleTriple TherapyTherapy withwith aa Statin,Statin, FibrateFibrate andand EzetimibeEzetimibe ) Methods:Methods: 3737 T2DMT2DM patientspatients (35%(35% female),female), mixedmixed dyslipidemiadyslipidemia withwith nono CVD.CVD. (~age(~age 59)59) ) AfterAfter 1212 weeksweeks ofof fenofibratefenofibrate 160160 mg,mg, simvastatinsimvastatin 20m20m mgmg oror theirtheir combination,combination, patientspatients
Load more

Recommended publications
  • Ezetimibe: a Novel Selective Cholesterol Absorption Inhibitor by Michele Koder, Pharm.D
    OREGON DUR BOARD NEWSLETTER A N E VIDENCE B ASED D RUG T HERAPY R ESOURCE COPYRIGHT 2003 OREGON STATE UNIVERSITY. ALL RIGHTS RESERVED Volume 5, Issue 2 Also available on the web and via e-mail list-serve at February 2003 http://pharmacy.orst.edu/drug_policy/newsletter_email.html Ezetimibe: A novel selective cholesterol absorption inhibitor By Michele Koder, Pharm.D. , OSU College of Pharmacy Ezetimibe (Zetia) is a novel selective cholesterol absorption inhibitor that was approved by the FDA in October 2002. Unlike statins (HMG-CoA reductase inhibitors) and bile acid sequestrants, ezetimibe does not inhibit hepatic cholesterol synthesis or increase bile acid secretion. In contrast, ezetimibe selectively inhibits the uptake of dietary cholesterol from enterocytes in the brush border of the intestinal lumen resulting in a decrease in the delivery of dietary cholesterol to the liver and a subsequent decrease in hepatic cholesterol stores and increased cholesterol clearance from the blood.1 Ezetimibe’s unique action has generated interest in its use in combination with other cholesterol-lowering agents. It is indicated for the treatment of primary hypercholesterolemia as monotherapy and in combination with a statin. Ezetimibe is also approved for homozygous familial hypercholesterolemia and homozygous sitosterolemia. TABLE 1: EZETIMIBE CLINICAL TRIAL SUMMARY Study / Design Population Treatment % Change LDL % Change HDL % Change TG Bays et al3 N=432 EZ 5 mg -15.7 +2.9 MC, R, DB, PC LDL 130-250mg/dl EZ 10 mg -18.5 +3.5 NS 12 wk; Phase II TG
    [Show full text]
  • SUMMARY of the PRODUCT CHARACTERISTICS 1. NAME of the MEDICINAL PRODUCT <Invented Name> 10 Mg/10 Mg Film-Coated Tablets
    SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <Invented name> 10 mg/10 mg film-coated tablets <Invented name> 20 mg/10 mg film-coated tablets <Invented name> 40 mg/10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION <Invented name> 10 mg/10 mg: Each film-coated tablet contains 10 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 20 mg/10 mg: Each film-coated tablet contains 20 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 40 mg/10 mg: Each film-coated tablet contains 40 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. Excipient with known effect: <Invented name> 10 mg/10 mg: Each film-coated tablet contains 111.2 mg of lactose (as lactose monohydrate). <Invented name> 20 mg/10 mg: Each film-coated tablet contains 168.6 mg of lactose (as lactose monohydrate). <Invented name> 40 mg/10 mg: Each film-coated tablet contains 286.0 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) <Invented name> 10 mg/10 mg: white to off-white oblong film-coated tablets. <Invented name> 20 mg/10 mg: yellow to light yellow oblong film-coated tablets. <Invented name> 40 mg/10 mg: pink oblong film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Primary Hypercholesterolaemia/Homozygous Familial Hypercholesterolaemia (HoFH) <Invented name> is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.
    [Show full text]
  • Zetia® (Ezetimibe) Tablets
    29480958T REV 14 ZETIA® (EZETIMIBE) TABLETS DESCRIPTION ZETIA (ezetimibe) is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. The chemical name of ezetimibe is 1-(4-fluorophenyl)- 3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C24H21F2NO3. Its molecular weight is 409.4 and its structural formula is: OH OH S SR N F F O Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Ezetimibe has a melting point of about 163°C and is stable at ambient temperature. ZETIA is available as a tablet for oral administration containing 10 mg of ezetimibe and the following inactive ingredients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, povidone USP, and sodium lauryl sulfate NF. CLINICAL PHARMACOLOGY Background Clinical studies have demonstrated that elevated levels of total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B), the major protein constituent of LDL, promote human atherosclerosis. In addition, decreased levels of high density lipoprotein cholesterol (HDL-C) are associated with the development of atherosclerosis. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including very-low- density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of coronary and cardiovascular morbidity and mortality has not been determined.
    [Show full text]
  • Efficacy of Combination Therapy of Rosuvastatin and Ezetimibe Vs
    Original Article DOI: 10.7860/JCDR/2017/30458.11004 Efficacy of Combination Therapy Internal Medicine Section of Rosuvastatin and Ezetimibe vs Rosuvastatin Monotherapy on Lipid Profile of Patients with Coronary Artery Disease SANDEEP JOSHI1, RUBY SHARMA2, HARBIR KAUR RAO3, UDIT NARANG4, NITIN GUPTA5 ABSTRACT baseline investigations and lifestyle modifications, Group I Introduction: Dyslipidaemia is one of the most important was started on rosuvastatin 10 mg once daily, while Group modifiable risk factor for the development of Coronary II was started on rosuvastatin 10 mg+ezetimibe 10 mg daily. Artery Disease (CAD). Although, statins are established as The fasting serum lipid profile was repeated initially after first line lipid-lowering therapy, they may not be able to 12 weeks and then after 24 weeks. The two groups were achieve treatment goals in significant number of patients. observed for side effects which were noted. Combination therapy of statin with a non-statin drug like Results: The combination therapy of rosuvastatin and Ezetimibe is a therapeutic option. ezetimibe resulted in significantly higher change in all Aim: To compare the efficacy and safety of Rosuvastatin/ lipid parameters (LDL-C, TC, TG, HDL-C) as compared to Ezetimibe combination therapy vs Rosuvastatin alone on the treatment with rosuvastatin alone. There was no difference in lipid profile of patients with CAD in Northern India. the adverse effects seen after treatment in the two groups. Materials and Methods: This randomized prospective Conclusion: Our study showed that combination therapy study was conducted on 80 patients of CAD presenting of ezetimibe with rosuvastatin can be used as an effective to Department of Medicine, Government Medical College, and safe therapy in high risk patients of CAD, especially in Patiala, Punjab, India.
    [Show full text]
  • CP.PMN.237 Bempedoic Acid (Nexletol)
    Clinical Policy: Bempedoic Acid (Nexletol), Bempedoic Acid/Ezetimibe (Nexlizet) Reference Number: CP.PMN.237 Effective Date: 09.01.20 Last Review Date: 02.21 Revision Log Line of Business: Commercial, HIM, Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description The following are adenosine triphosphate-citrate lyase (ACL) inhibitors requiring prior authorization: bempedoic acid (Nexletol™) and bempedoic acid/ezetimibe (Nexlizet™). Nexlizet contains ezetimibe, which is a cholesterol absorption inhibitor. FDA Approved Indication(s) Nexletol and Nexlizet are indicated for use as adjuncts to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Limitation(s) of use: The effect of Nexletol and Nexlizet on cardiovascular morbidity and mortality has not been determined. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Nexletol and Nexlizet are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Heterozygous Familial Hypercholesterolemia and Atherosclerotic Cardiovascular Disease (must meet all): 1. Diagnosis of one of the following (a or b): a. ASCVD as evidenced by a history of any one of the following conditions (i-vii): i. Acute coronary syndromes; ii. Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging); iii.
    [Show full text]
  • Information for the User Ezetimibe/Simvastatin Clonmel 10 Mg/10 Mg Tablets Ezetimibe/Simvastatin Clonmel 10 Mg
    Package leaflet: Information for the user Ezetimibe/Simvastatin Clonmel 10 mg/10 mg tablets Ezetimibe/Simvastatin Clonmel 10 mg/20 mg tablets Ezetimibe/Simvastatin Clonmel 10 mg/40 mg tablets Ezetimibe/Simvastatin Clonmel 10 mg/80 mg tablets Ezetimibe/simvastatin Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Ezetimibe/Simvastatin Clonmel is and what it is used for 2. What you need to know before you take Ezetimibe/Simvastatin Clonmel 3. How to take Ezetimibe/Simvastatin Clonmel 4. Possible side effects 5. How to store Ezetimibe/Simvastatin Clonmel 6. Contents of the pack and other information 1. What Ezetimibe/Simvastatin Clonmel is and what it is used for Ezetimibe/Simvastatin Clonmel is a medicine used to lower levels of total cholesterol, “bad” cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, Ezetimibe/Simvastatin Clonmel raises levels of “good” cholesterol (HDL cholesterol). Ezetimibe/Simvastatin Clonmel contains the active substances ezetimibe and simvastatin. Ezetimibe/Simvastatin Clonmel works to reduce your cholesterol in two ways.
    [Show full text]
  • 10 Mg/80 Mg Filmtabletten
    Bundesinstitut für Arzneimittel und Medizinprodukte Public Assessment Report Decentralised Procedure DE/H/3895/001-004/DC Atozet 10 mg/10 mg; 10 mg/20 mg; 10 mg/40 mg; 10 mg/80 mg Filmtabletten DE/H/3896/001-004/DC Kexrolt 10 mg/10 mg; 10 mg/20 mg; 10 mg/40 mg; 10 mg/80 mg Filmtabletten DE/H/3897/001-004/DC Orvatez 10 mg/10 mg; 10 mg/20 mg; 10 mg/40 mg; 10 mg/80 mg Filmtabletten DE/H/3898/001-004/DC Tioblis 10 mg/10 mg; 10 mg/20 mg; 10 mg/40 mg; 10 mg/80 mg Filmtabletten Active substances: Ezetimibe/Atorvastatin Marketing authorisation holder in the Reference Member State, Germany: MSD Sharp & Dohme GmbH Date: 15.05.2015 TABLE OF CONTENTS I. RECOMMENDATION .............................................................................................................. 3 II. EXECUTIVE SUMMARY ..................................................................................................... 3 II.1 Problem statement ................................................................................................................... 3 II.2 About the product ................................................................................................................... 3 II.3 General comments on the submitted dossier ........................................................................ 4 II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles 4 III. SCIENTIFIC OVERVIEW AND DISCUSSION ................................................................. 4 III.1 Quality aspects ........................................................................................................................
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Efficacy and Safety of Triplet Therapy With
    Interactive! Click on any of Efficacy and Safety of Triplet Therapy With Bempedoic Acid, Ezetimibe, TAP TO RETURN these bubbles to TO KIOSK MENU jump to each and Atorvastatin in Patients With Hypercholesterolemia section Diane E. MacDougall, MS1; John Rubino, MD2; Lulu Ren Sterling, PhD1; Jeffrey C. Hanselman, MS1; Stephen J. Nicholls, MD, PhD3 Results & Methods 1Esperion Therapeutics Inc., Ann Arbor, MI; 2PMG Research of Raleigh, Raleigh, NC; Results 3Monash Cardiovascular Research Centre, Monash University, Melbourne, VIC, Australia Conclusions INTRODUCTION METHODS • Patients with hypercholesterolemia often fail to achieve sufficient cholesterol lowering, despite the use of guideline- recommended lipid-lowering therapies1-3 STUDY DESIGN AND TREATMENT • Bempedoic acid is an oral, first-in-class ATP-citrate lyase inhibitor in development for treating hypercholesterolemia4,5 • Phase 2, randomized, double-blind, placebo-controlled study – The active form of bempedoic acid (bempedoyl-CoA) inhibits ATP-citrate lyase, an enzyme upstream of • The study consisted of 2 phases (Figure 1): HMG-CoA reductase (the target of statins) in the cholesterol biosynthesis pathway – A 6-week screening/washout period during which patients – Bempedoic acid is a prodrug that is activated in the liver by very long-chain acyl-CoA synthetase 1 (ACSVL1) discontinued lipid-lowering drugs and nutritional supplements – A double-blind treatment period in which patients were – ACSVL1 expression is limited to the liver; therefore, bempedoic acid is not converted to bempedoyl-CoA in randomized 2:1 to treatment with triplet therapy (bempedoic acid skeletal muscle 180 mg + ezetimibe 10 mg + atorvastatin 20 mg) or placebo once • In phase 3 clinical trials, bempedoic acid significantly lowered low-density lipoprotein cholesterol (LDL-C) when daily for 6 weeks administered alone or as an add-on to background lipid-lowering therapy6-9 OBJECTIVE FIGURE 1.
    [Show full text]
  • Zetia® (Ezetimibe) Tablets
    25751841T REV 03 ZETIA® (EZETIMIBE) TABLETS DESCRIPTION ZETIA (ezetimibe) is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. The chemical name of ezetimibe is 1-(4-fluorophenyl)- 3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C24H21F2NO3. Its molecular weight is 409.4 and its structural formula is: OH OH S R S N F F O Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Ezetimibe has a melting point of about 163°C and is stable at ambient temperature. ZETIA is available as a tablet for oral administration containing 10 mg of ezetimibe and the following inactive ingredients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, povidone USP, and sodium lauryl sulfate NF. CLINICAL PHARMACOLOGY Background Clinical studies have demonstrated that elevated levels of total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B), the major protein constituent of LDL, promote human atherosclerosis. In addition, decreased levels of high density lipoprotein cholesterol (HDL-C) are associated with the development of atherosclerosis. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including very-low- density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of coronary and cardiovascular morbidity and mortality has not been determined.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Report on the Deliberation Results February 26, 2019 Pharmaceutical
    Report on the Deliberation Results February 26, 2019 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Rosuzet Combination Tablets LD Rosuzet Combination Tablets HD Non-proprietary Name Ezetimibe / Rosuvastatin Calcium (JAN*) Applicant MSD K.K. Date of Application May 22, 2018 Results of Deliberation In its meeting held on February 21, 2019, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product. The re-examination period is 4 years. The drug products are not classified as a poisonous drug or a powerful drug. Condition of Approval The applicant is required to develop and appropriately implement a risk management plan. *Japanese Accepted Name (modified INN) This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. Review Report February 8, 2019 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by the Pharmaceuticals and Medical Devices Agency (PMDA). Brand Name Rosuzet Combination Tablets LD Rosuzet Combination Tablets HD Non-proprietary Name Ezetimibe / Rosuvastatin Calcium Applicant MSD K.K.
    [Show full text]